Pandemic (H1N1) 2009 Outbreak at Canadian Forces Cadet Camp

Rhonda Y. Kropp, Laura E. Bogaert, Robert Barber, Francois-William Tremblay, Robert Ennis, Martin Tepper, Robert Pless, Nathalie Bastien, Yan Li, Carole Beaudoin, James Anderson, Louise Pelletier, and Rachel Rodin

We conducted a case–control study to describe the clinical and epidemiologic characteristics of an outbreak of pandemic (H1N1) 2009 at a Canadian military cadet training center. We found that asthma and obesity confer greater risk for infection. Viral shedding was detected by PCR up to 18 days after symptom onset.

On July 29, 2009, the Public Health Agency of Canada was notified of an outbreak of pandemic (H1N1) 2009 at the Army Cadet Summer Training Centre Argonaut at Canadian Forces Base, Gagetown, New Brunswick. The Cadet Summer Training Centre camp opened in early July and ran sessions lasting 2–6 weeks. The camp setting was semiclosed, with limited movement on and off camp. A case–control study was conducted to describe transmission, clinical characteristics, viral shedding, and risk factors for infection.

The Study

Approximately 506 cadets, 12–18 years of age, and 322 staff cadets, officers, and support staff lived on camp premises. All persons at the camp were invited to participate. This study received expedited approval from the Health Canada Research Ethics Board. Participants were interviewed in person at the camp or by telephone; swab specimens were collected by on-site nurses. Samples were sent to the National Microbiology Laboratory for testing using reverse transcription–PCR and primer sets developed by the US Centers for Disease Control and Prevention (/). Specimens were cultured in primary CMK cells (Viromed Laboratories, Inc., Minnetonka, MN, USA) and the hemagglutinin titer was checked at days 6 and 10.

A modified case definition for pandemic (H1N1) 2009 infection was developed based on Canada’s surveillance case definition for influenza-like illness. Symptom onset was defined as earliest date of onset of self-reported history of fever or cough. The case definition is outlined in Table 1.

During August 3–27, 2009, we conducted 144 face-to-face and 21 phone interviews. Approximately 20% of cadets and 20% of staff cadets, officers, and support staff participated. Of the 165 participants, 56 were classified as confirmed cases, 24 as suspected cases, and 85 as controls. Participant age ranged from 13 to 43 years; 88% were 13–18 years of age, and 55% were male. No statistically significant demographic differences (p<0.05) were observed between confirmed cases, suspected cases, or controls.

The epidemic curve (Figure) summarizes the outbreak among those with known symptom onset date for cases (n = 54), suspected cases (n = 21), and 27 additional cases of fever and cough identified by the camp Health Care Centre (HCC) but not included in the study. The minimum camp attack rate for cases/suspected cases and HCC cases not in the study was 13.5% (112/828), 14.0% among cadets (71/506) and 12.7% among staff cadets and officers (41/322).

The outbreak was identified on July 17. In response, respiratory etiquette and hand hygiene were emphasized; camp residents were encouraged to seek care if ill. Those having fever and cough were isolated for 7 days, until parents came, or until laboratory results returned negative. Group outdoor activities stopped on July 23; all group activities were cancelled as of July 25. Some cadets were fast-tracked to graduate early, and arrival of new cadets

Table 1. Case definitions for pandemic (H1N1) 2009 infection, Army Cadet Summer Training Centre Argonaut at Canadian Forces Base, Gagetown, New Brunswick, Canada, 2009

| Table 1. Case definitions for pandemic (H1N1) 2009 infection, Army Cadet Summer Training Centre Argonaut at Canadian Forces Base, Gagetown, New Brunswick, Canada, 2009 |
|----------------------------------|
| **Confirmed cases** |
| Persons who |
| 1. Had laboratory-confirmed pandemic (H1N1) 2009 influenza infection OR |
| 2. Reported fever AND cough while at camp, excluding those who had negative PCR results for pandemic (H1N1) 2009 within 5 days after symptom onset |
| **Suspected cases** |
| Persons who |
| 1. Reported fever OR cough with ≥2 of the following symptoms: sore throat, nausea, nasal congestion, chills OR |
| 2. Reported fever and cough and had negative PCR results for pandemic (H1N1) 2009 within 5 days after symptom onset |
| Controls |
| Persons who |
| 1. Did not report fever or cough OR |
| 2. Reported fever or cough but without ≥2 of the following symptoms: sore throat, nausea, nasal congestion, chills |

Author affiliations: Public Health Agency of Canada, Ottawa, Ontario, Canada (R.Y. Kropp, F-W. Tremblay, R. Pless, L. Pelletier, R. Rodin); Department of National Defence Headquarters, Ottawa (L.E. Bogaert, R. Barber, R. Ennis, M. Tepper, J. Anderson); and Public Health Agency of Canada, Winnipeg, Manitoba, Canada (N. Bastien, Y. Li, C. Beaudoin)

DOI: 10.3201/eid1612.100451

1986  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 12, December 2010
was delayed 2 weeks. Mass screening for fever and cough was undertaken on August 6, before the arrival of new cadets; all the new cadets were screened on arrival.

No activity or exposure was linked to increased risk for illness (data not shown). All but 1 person with a suspected or confirmed case reported symptoms; 58/85 (68.2%) of controls also reported symptoms during the outbreak period. Odds of experiencing shortness of breath, chest pain, sputum production, vomiting, rhinorrhea, nose bleeds, or change in level of awareness were all >5× higher for those with cases/suspected cases than for controls (Table 2). The mean number of symptoms among those with symptomatic cases/suspected cases was greater than among symptomatic controls (8.7 vs. 3.4; p<0.001). This relationship held true when comparing those with cases/suspected cases with symptomatic controls who had negative PCR results.

Of the 78 persons with symptomatic/suspected cases for whom complete information was available, 25 (32.1%) had recovered by the interview; median symptom duration was 7 and 9 days, respectively. Symptom duration ≥10 days was reported by 40% of persons with cases/suspected cases whose symptoms had resolved and 47% of those with unresolved symptoms. Median time from symptom onset to illness peak was 2 days (range 1–14 days). With the exception of cough, sputum production, and malaise, symptoms peaked rapidly (24–48 hours) after onset.

Overall, 86.1% of persons with cases/suspected cases accessed the HCC; none were hospitalized. Oseltamivir was given to 2 persons with confirmed cases who had co-morbid conditions (asthma and kidney disease). Forty-four persons with cases/suspected cases (55.7%) were not isolated because they did not seek treatment at the HCC or while both fever and cough were present.

Eight persons had positive PCR results for pandemic (H1N1) 2009 7–18 days after symptom onset, and live virus was detected up to 14 days after symptom onset. All but 1 of these persons were capable of transmitting virus given upper respiratory symptoms, and 2 reported diarrhea and vomiting on the day the swab sample was obtained. Four persons had live virus detected after day 7 of illness (up to 14 days); 2 of these reported comorbid conditions.

Persons with confirmed and suspected cases did not differ with regard to comorbidity or risk factors, except for seasonal influenza vaccination; 6/48 (12.5%) of persons with confirmed cases reported having received the seasonal influenza vaccine in the year of the study versus 8/22 (36.4%) of those with suspected cases (odds ratio 4.0; p<0.05). No difference was found in the proportion of those with cases/suspected cases and controls reporting seasonal influenza vaccination during the current year or past 2 years.

The odds of reporting ≥1 comorbidity was >2.7× higher for persons with case/suspected cases than for controls (p<0.05) and for asthma >3.9× higher (p < 0.05). The odds of being obese were >3× higher for persons with cases/suspected cases (odds ratio 3.4, 95% confidence interval 1.0–10.9).

Conclusions

In accordance with national recommendations (2), antiviral drugs were not used for control; transmission appeared to be reduced through nonpharmaceutical measures. Multiple index cases could not be ruled out. No individual activity or exposure was linked to increased risk for illness.

High rates of obesity have been noted among hospitalized patients with pandemic (H1N1) 2009 (3–6). This study suggests obesity is a risk factor for infection or clinical illness and given low prevalence of comorbid conditions may stand alone as a risk factor. Consistent with international studies (7), vaccination for seasonal influenza was neither protective nor a risk factor for acquiring pandemic (H1N1) 2009. One third of case-patients reported change in level of awareness, which suggests the potential for mild neurologic sequelae. Neurologic complications of influenza infection have been reported in hospitalized children (8,9).

Seven of 8 participants who had positive PCR results for pandemic (H1N1) 2009 ≥7 days after symptom onset...
were capable of transmitting virus, given their upper respiratory symptoms on the day the swab sample was obtained. Studies of seasonal influenza indicate median viral shedding of 7–8 days after illness onset, with titers low or undetectable by day 5, although prolonged shedding has been reported (10–13). In this study, test results for pandemic (H1N1) 2009 were positive by culture up to 14 days and by PCR up to 18 days after symptom onset. This and other studies describe longer shedding periods for pandemic (H1N1) 2009 as compared with seasonal influenza (10,13–15).

Study limitations should be acknowledged. The case definition included self-reported fever and cough. Therefore, misclassification of persons with illnesses other than pandemic (H1N1) 2009 may have occurred. Convenience sampling was used, so participants may differ from nonparticipants; complete demographics for the camp were not available for comparison. A small proportion of phone interviews were conducted <6 weeks after symptom onset, raising the possibility of recall bias.

Infection control procedures likely contributed to the control of transmission in the absence of antiviral drug use or early treatment for contacts. Shedding in otherwise healthy adolescents and young adults may be longer than shedding of seasonal influenza viruses, which may have implications for public health planning.

### Table 2. Frequency of reported symptoms of pandemic (H1N1) 2009 infection, Army Cadet Summer Training Centre Argonaut at Canadian Forces Base, Gagetown, New Brunswick, Canada, 2009*

| Symptoms                   | All participants, n = 165 | Persons with confirmed/suspected cases, † n = 80 | Controls, n = 85 | OR (95% CI)‡ |
|----------------------------|---------------------------|-----------------------------------------------|-----------------|-------------|
| None                       | 28/165 (17.0)             | 1/80 (1.3)                                   | 27/85 (31.8)    |             |
| **Systemic**               |                           |                                              |                 |             |
| Fever                      | 56/164 (34.1)             | 55/80 (68.8)                                 | 1/84 (1.2)      |             |
| Chills                     | 44/165 (26.7)             | 41/80 (51.2)                                 | 3/85 (3.5)      |             |
| Headache                   | 58/165 (35.2)             | 39/80 (48.8)                                 | 19/85 (22.4)    | 3.3 (1.7–6.5)§ |
| Prostration                | 52/164 (31.7)             | 37/46 (49.6)                                 | 15/85 (17.6)    | 4.1 (2.0–8.4)¶ |
| Malaise                    | 67/165 (40.6)             | 47/80 (58.8)                                 | 20/85 (23.5)    | 4.6 (2.4–9.0)¶ |
| Arthralgia                 | 19/165 (11.5)             | 13/80 (16.2)                                 | 6/85 (7.1)      | 2.6 (0.9–7.1) |
| Myalgia                    | 26/165 (15.8)             | 20/80 (25.0)                                 | 6/85 (7.1)      | 4.4 (1.7–11.6)§ |
| **Lower respiratory**      |                           |                                              |                 |             |
| Cough                      | 97/165 (58.8)             | 76/80 (95.0)                                 | 21/85 (24.7)    |             |
| Sputum production          | 33/164 (20.1)             | 26/79 (32.9)                                 | 7/84 (8.2)      | 5.5 (2.2–13.5)¶ |
| Shortness of breath        | 30/165 (18.2)             | 26/80 (32.5)                                 | 4/85 (4.7)      | 9.8 (3.2–29.5)¶ |
| Chest pain                 | 14/165 (8.5)              | 13/80 (16.2)                                 | 1/85 (1.2)      | 16.3 (2.1–127.8)§ |
| **Upper respiratory**      |                           |                                              |                 |             |
| Sore throat                | 76/164 (46.3)             | 56/80 (70.0)                                 | 20/84 (24.8)    |             |
| Nasal congestion           | 76/164 (46.3)             | 55/79 (69.6)                                 | 21/85 (24.7)    |             |
| Sneezing                   | 27/164 (16.5)             | 20/79 (25.3)                                 | 7/85 (8.2)      | 3.8 (1.5–9.5)§ |
| Runny nose                 | 41/159 (25.8)             | 32/75 (42.7)                                 | 9/84 (10.7)     | 6.2 (2.7–14.2)¶ |
| Nosebleeds                 | 10/165 (6.1)              | 9/80 (11.2)                                  | 1/85 (1.2)      | 10.6 (1.3–86.1)# |
| **Gastrointestinal**       |                           |                                              |                 |             |
| Nausea                     | 50/165 (30.3)             | 42/80 (52.5)                                 | 8/85 (9.4)      |             |
| Abdominal pain             | 28/165 (17.0)             | 17/80 (21.2)                                 | 11/85 (12.9)    | 1.8 (0.8–4.2) |
| Diarrhea                   | 26/165 (15.8)             | 19/80 (23.8)                                 | 7/85 (8.2)      | 3.5 (1.4–8.8)¶ |
| Vomiting                   | 24/165 (14.5)             | 20/80 (25.0)                                 | 4/85 (4.7)      | 6.8 (2.2–20.8)¶ |
| **Neurologic**             |                           |                                              |                 |             |
| Seizures                   | 0/164 (0.0)               | 0/80 (0.0)                                   | 0/85 (0.0)      | NA          |
| Change in awareness        | 29/165 (17.6)             | 25/80 (31.2)                                 | 4/85 (4.7)      | 9.2 (3.0–27.9)¶ |
| **Other**                  |                           |                                              |                 |             |
| Conjunctivitis             | 2/164 (1.2)               | 1/79 (1.3)                                   | 1/85 (1.2)      | 1.0 (0.1–17.5) |
| Other**                    | 16/165 (9.7)              | 14/80 (17.5)                                 | 2/85 (2.4)      | 8.8 (2.0–40.1)§ |
| Mean no. symptoms          | 6.5                       | 8.7                                          | 3.4             |             |

*One person reported no symptoms but was PCR and culture positive. OR, odds ratio; CI, confidence interval; NA, not applicable.
†Fever and nausea reported by a greater proportion of cases than suspected cases (p<0.001 and p = 0.02, respectively). Cases and suspected cases did not differ significantly in frequency of symptoms not in the case definition or median number of symptoms and have therefore been combined here.
‡Odds ratios were not calculated for symptoms included in the case definition (fever, chills, cough, sore throat, congestion, nausea).
§p<0.01.
¶p<0.001.
#p<0.05.
**Other symptoms reported: bilateral ear infection, bruising, ear pain, ear popping, eye pain, hot flashes, jaw pain, loss of appetite, loss of voice, rib pain, swelling of eyes, swollen tonsils, toothache (1 person each); dizziness (3 persons). All persons who reported symptoms in this category had ≥1 other reported symptom.
Acknowledgments

We thank everyone at the Argonaut cadet camp for their invaluable assistance and support on site. Specifically, we thank Kenneth M. Fells for welcoming and supporting the team at the camp and Barbara Butler and Peggy Fry and the nursing staff at the HCC for their unwavering support throughout data collection. This study would not have been possible without their support and assistance.

This study was a collaboration between representatives from the Public Health Agency of Canada and the Department of National Defence, Canadian Forces Health Services Group Headquarters. Funding for this study was provided by the Public Health Agency of Canada.

At the time this work was conducted, Ms Kropp was an epidemiologist and policy advisor with the Public Health Agency of Canada. Currently, she is the director of the Travel Health Division in the same agency. Her research interests include the epidemiology, prevention, and control of infectious diseases.

References

1. Centers for Disease Control and Prevention. Realtime RTPCR (rRT-PCR) Protocol for Detection and Characterization of Swine Influenza (version 2009).
2. Public Health Agency of Canada. Use of antivirals to treat H1N1 flu virus [cited 2010 Feb 15]. http://www.phac-aspc.gc.ca/alert-alerte/h1n1/antiviral-antiviraux05-01-eng.php
3. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med. 2010;38(Suppl):e91–7. DOI: 10.1097/CCM.0b013e3181c92eeb
4. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, LaCroix J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. AMA. 2009;302:1872–9. Epub 2009 Oct 12. DOI: 10.1001/jama.2009.1496
5. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Lovie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States April–June 2009. N Engl J Med. 2009;361:1935–44. DOI: 10.1056/NEJMoa0906695
6. Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:749–52.
7. Centers for Disease Control and Prevention. Effectiveness of 2008–09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)—United States, May–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1241–5.
8. Maricich SM, Neul JL, Lotze TE, Cazacu AC, Uyeki TM, Demmler GI, et al. Neurologic complications associated with influenza A in children during the 2003–2004 influenza season in Houston, Texas. Pediatrics. 2004;114:e626–33. DOI: 10.1542/peds.2004-0143
9. Centers for Disease Control and Prevention. Neurologic complications associated with novel influenza A (H1N1) virus infection in children—Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:773–8.
10. World Health Organization Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12:81–7.
11. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65. DOI: 10.1016/S0140-6736(04)16934-1
12. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995;172:1352–5.
13. Lee N, Chan PKS, Hui DSC, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. JID. 2009;200:492–500. DOI: 10.1086/600383
14. Witkop C, Duffy MR, Macias EA, Gibbons TF, Escobar JD, Burwell KN, et al. Novel influenza A (H1N1) outbreak at the US Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med. 2010;38:121–6. DOI: 10.1016/j.amepre.2009.10.005
15. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al. Clinical features of initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361:2507–17. DOI: 10.1056/NEJMoa0906612

Address for correspondence: Rhonda Y. Kropp, Travel Health, Public Health Agency of Canada, 130 Colonnade Rd, Rm 396B, Ottawa, Ontario K1A 0K9, Canada; email: rhonda.kropp@phac-aspc.gc.ca